Cargando…
SOX17 enhancer variants disrupt transcription factor binding and enhancer inactivity drives pulmonary hypertension
BACKGROUND: Pulmonary arterial hypertension (PAH) is a rare disease characterised by remodelling of the pulmonary arteries, increased vascular resistance and right heart failure. Genome-wide association studies (GWAS) of idiopathic/heritable PAH established novel genetic risk variants including cons...
Autores principales: | Walters, Rachel, Vasilaki, Eleni, Aman, Jurjan, Chen, Chien-Nien, Wu, Yukyee, Liang, Olin D, Ashek, Ali, Dubois, Olivier, Zhao, Lin, Sabrin, Farah, Cebola, Inês, Ferrer, Jorge, Morrell, Nicholas W, Klinger, James R, Wilkins, Martin R, Zhao, Lan, Rhodes, Christopher J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7614572/ https://www.ncbi.nlm.nih.gov/pubmed/37066790 http://dx.doi.org/10.1161/CIRCULATIONAHA.122.061940 |
Ejemplares similares
-
TLR7/8 activation induces autoimmune vasculopathy and causes severe pulmonary arterial hypertension
por: Yeh, Fu-Chiang, et al.
Publicado: (2023) -
Recent advances in pulmonary arterial hypertension
por: Wilkins, Martin R., et al.
Publicado: (2018) -
Light at the ENDothelium-role of Sox17 and Runx1 in endothelial dysfunction and pulmonary arterial hypertension
por: Simmons Beck, Robert, et al.
Publicado: (2023) -
Pancreatic Islet Transcriptional Enhancers and Diabetes
por: Cebola, Inês
Publicado: (2019) -
An organ-on-chip model of pulmonary arterial hypertension identifies a BMPR2-SOX17-prostacyclin signalling axis
por: Ainscough, Alexander J., et al.
Publicado: (2022)